The FDA on September 21, 2022, granted regular approval to RETEVMO® (Selpercatinib) for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with a REearranged during Transfection (RET) gene fusion, as detected by an FDA-approved test. RETEVMO® is a product of Eli Lilly and Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
